Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

Item

http://www.wikidata.org/entity/Q34732473

Q34732473

about

Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Myeloid-derived cells are key targets of tumor immunotherapy CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners Chemoimmunotherapy.Redirecting the immune response: role of adoptive T cell therapy.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model Profound impairment of adaptive immune responses by alkylating chemotherapy Targeting T cells with bispecific antibodies for cancer therapy Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Unravelling the complexity of cancer-immune system interplay.Stimulating natural killer cells to protect against cancer: recent developments.Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.Chemoimmunotherapy: reengineering tumor immunity.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Exploiting dendritic cells in the development of cancer vaccines.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity Therapeutic vaccines for cancer: an overview of clinical trials.Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy.G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses Role of Interferon Regulatory Factor 1 in Governing Treg Depletion, Th1 Polarization, Inflammasome Activation and Antitumor Efficacy of Cyclophosphamide.Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide.Ferulic Acid against Cyclophosphamide-Induced Heart Toxicity in Mice by Inhibiting NF-κB Pathway.Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.

P2860

Q27334215-C543275B-87DD-49BB-9A89-C23EB1C6BF69 Q28388246-5394684F-3646-4B2B-BE42-7C3C08D23728 Q30533257-7B9CBB41-64F5-4307-96B5-FD747B5619BD Q33653210-C60ABE09-9D91-426C-90D3-4A28A336D0B1 Q33754618-35C032C9-DC45-4659-A750-4874159206D7 Q33945653-17399542-52CA-4061-A57C-F4AECF8DD409 Q34058792-B365DF4B-6FE9-457F-9BA9-C80A211DE2A1 Q34123238-C6F2860C-0742-4016-83DB-ADD8CC795C4F Q34187201-7AF1D49B-15C7-4FFB-A891-45F810F912F0 Q34634616-17BD3D63-0215-44A8-978E-D46E50C8C3AF Q34732294-CFB46281-1A27-40E6-AD52-27A3686442A0 Q34759603-826B33B6-7F1B-4B43-9EC7-CBADA17A2B5C Q34982519-869D74FA-4F7D-465D-B19A-E499FBF118BE Q34985537-B95C3458-98D9-446F-9C05-5CC6BE4AE230 Q35203752-F5137CD0-E2CE-4DBE-B528-092B586500E6 Q35925964-419189FD-1236-4672-848C-96F5E7451479 Q36193963-57D52ED7-352A-460B-B6A6-B7111CDFFC7A Q36403509-8F9A58F6-EFFB-4AF3-B68E-7A392E642E0C Q36600960-11D09151-E4E5-476A-BEAE-74F0DD877825 Q36922577-2078A32F-DC8A-4302-819D-EF72849CEFD1 Q37220742-F2DB2971-38C1-41BF-8C47-D4AC49942244 Q37741161-D600D554-863D-47E8-B1A9-1F1E6B20F230 Q37765590-B9ABCDCF-774D-4772-8881-87E24C9832F9 Q37877269-30B4D6E1-C05E-40CE-B028-3750CA1D0DA9 Q37969356-98DE5062-C98F-4CD8-9745-CF21903FB235 Q38079749-AB059B24-064E-4CA6-9BD5-9B43DB533F0B Q38101679-F6B794A2-E586-4E87-BDEA-FE9E4F8AF11D Q38148774-C4F09F43-92E9-4F0A-8D6E-62FEE159C2E0 Q38149916-2BFC3483-5EF7-4B16-B38B-5BB14B7D1B23 Q38161367-DAE8E13C-4470-4F68-8266-F001DF7FD475 Q38174601-FC0985C4-6016-482C-9881-46D3A03BEECD Q38227030-54EADDD5-2E19-4283-B922-1BBE50845AB6 Q39061560-E9D8E055-BF68-4EAF-8B2D-81B17010F0ED Q39637537-89334879-703A-46B9-87A6-20BEFC9CDCAC Q41928461-DF3BA434-0790-47EC-8E3F-B44CA4A74B9F Q41956513-4D41B6D7-94D6-4BB8-B6B8-23EE67D76DD5 Q41991396-99FA7FEA-90FA-4690-9752-6B5EB9E55EE8 Q42113273-86AC8E24-E914-49A8-8789-38A1566CD5CB Q42126352-379A2AEC-2261-478F-8EBE-155242EA6F42 Q45716103-4F80289F-A857-4E10-86E7-286B87494A0E

P2860

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

Item

http://www.wikidata.org/entity/Q34732473

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Recovery from cyclophosphamide ...... ted with the TLR3 agonist poly

@nl

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@ast

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@en

type

Item

label

Recovery from cyclophosphamide ...... ted with the TLR3 agonist poly

@nl

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@ast

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@en

prefLabel

Recovery from cyclophosphamide ...... ted with the TLR3 agonist poly

@nl

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@ast

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@en

P1476

Recovery from cyclophosphamide ...... ith the TLR3 agonist poly(I:C)

@en

P2093

Ahmed Khafagy

http://www.w3.org/2001/XMLSchema#string

Alberto J Montero

http://www.w3.org/2001/XMLSchema#string

Amir A Al-Khami

http://www.w3.org/2001/XMLSchema#string

C Marcela Díaz-Montero

http://www.w3.org/2001/XMLSchema#string

David J Cole

http://www.w3.org/2001/XMLSchema#string

Osama Naga

http://www.w3.org/2001/XMLSchema#string

P2860

The multiple personalities of the chemokine receptor CCR7 in dendritic cells

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive immunotherapy for cancer: building on success

Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

P304

2030-2040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.0801829

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

Mohamed L. Salem

Sabry A El-Naggar

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23989301

http://www.w3.org/2001/XMLSchema#string

P698

19201856

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

3066095

http://www.w3.org/2001/XMLSchema#string

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

about

P2860

P2860

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932